BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...was EVP of operations for the CSL Behring unit of CSL Ltd. (ASX:CSL). Kendrion partnered with Kamada Ltd....
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

...epithelial thickening in the esophagus. Ongoing work includes developing small molecule inhibitors of the pathway. Kamada Ltd....
...Co. Ltd. (Tokyo:4502; NYSE:TAK) market Glassia, an IV formulation of AAT, to treat AAT deficiency. Kamada...
BioCentury | Feb 8, 2019
Finance

Earnings on deck

...London; (C) Six-month EPS Company Date Pre/post mkt 4Q18 EPS est 4Q17 EPS Expected chg Kamada Ltd....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy Kamada Ltd....
BioCentury | Oct 6, 2017
Finance

High as a Kite

...NASDAQ:CTXR) 8/3/17 $6.8 $27.0 $26.0 -4% Spark Therapeutics Inc. (NASDAQ:ONCE) 8/3/17 $402.5 $2,777.5 $3,258.5 17% Kamada Ltd....
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave...
BioCentury | Sep 1, 2017
Clinical News

FDA approves Kamada anti-rabies therapy Kedrab

...animal. The anti-rabies IgG should be given concurrently with a full course of rabies vaccine. Kamada...
...Kedrion S.p.A. (Barga, Italy) has exclusive rights from Kamada to commercialize Kedrab in the U.S. Kamada...
...of the U.S. Kedrion declined to provide details, and Kamada did not respond to inquiries. Kamada Ltd....
BioCentury | Aug 25, 2017
Company News

FDA approves Kamada's anti-rabies therapy

...animal. The anti-rabies IgG should be given concurrently with a full course of rabies vaccine. Kamada...
...Kedrion S.p.A. (Barga, Italy) has exclusive rights from Kamada to commercialize Kedrab in the U.S. Kamada...
...to inquiries. On Friday, Kamada gained $0.25 to $4.55 on NASDAQ. Jaime De Leon human anti-rabies IgG therapy KamRAB KedRAB Kamada Ltd. Kedrion...
BioCentury | Aug 4, 2017
Financial News

Follow-on Roundup: Actinium, Kamada, Tetraphase

...Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease...
...acute myelogenous leukemia (AML). The candidate is an anti- CD45 mAb (BC8) labeled with iodine-131. Kamada...
...FDA for the broad-spectrum fluorocycline antibiotic in 1Q18. Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y. Kamada Ltd....
Items per page:
1 - 10 of 107
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...was EVP of operations for the CSL Behring unit of CSL Ltd. (ASX:CSL). Kendrion partnered with Kamada Ltd....
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

...epithelial thickening in the esophagus. Ongoing work includes developing small molecule inhibitors of the pathway. Kamada Ltd....
...Co. Ltd. (Tokyo:4502; NYSE:TAK) market Glassia, an IV formulation of AAT, to treat AAT deficiency. Kamada...
BioCentury | Feb 8, 2019
Finance

Earnings on deck

...London; (C) Six-month EPS Company Date Pre/post mkt 4Q18 EPS est 4Q17 EPS Expected chg Kamada Ltd....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy Kamada Ltd....
BioCentury | Oct 6, 2017
Finance

High as a Kite

...NASDAQ:CTXR) 8/3/17 $6.8 $27.0 $26.0 -4% Spark Therapeutics Inc. (NASDAQ:ONCE) 8/3/17 $402.5 $2,777.5 $3,258.5 17% Kamada Ltd....
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave...
BioCentury | Sep 1, 2017
Clinical News

FDA approves Kamada anti-rabies therapy Kedrab

...animal. The anti-rabies IgG should be given concurrently with a full course of rabies vaccine. Kamada...
...Kedrion S.p.A. (Barga, Italy) has exclusive rights from Kamada to commercialize Kedrab in the U.S. Kamada...
...of the U.S. Kedrion declined to provide details, and Kamada did not respond to inquiries. Kamada Ltd....
BioCentury | Aug 25, 2017
Company News

FDA approves Kamada's anti-rabies therapy

...animal. The anti-rabies IgG should be given concurrently with a full course of rabies vaccine. Kamada...
...Kedrion S.p.A. (Barga, Italy) has exclusive rights from Kamada to commercialize Kedrab in the U.S. Kamada...
...to inquiries. On Friday, Kamada gained $0.25 to $4.55 on NASDAQ. Jaime De Leon human anti-rabies IgG therapy KamRAB KedRAB Kamada Ltd. Kedrion...
BioCentury | Aug 4, 2017
Financial News

Follow-on Roundup: Actinium, Kamada, Tetraphase

...Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease...
...acute myelogenous leukemia (AML). The candidate is an anti- CD45 mAb (BC8) labeled with iodine-131. Kamada...
...FDA for the broad-spectrum fluorocycline antibiotic in 1Q18. Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), New York, N.Y. Kamada Ltd....
Items per page:
1 - 10 of 107